[go: up one dir, main page]

GT200600434A - Tieno[2,3-b]piridin-5-carbonitrilos como inhibidores de proteina quinasa - Google Patents

Tieno[2,3-b]piridin-5-carbonitrilos como inhibidores de proteina quinasa

Info

Publication number
GT200600434A
GT200600434A GT200600434A GT200600434A GT200600434A GT 200600434 A GT200600434 A GT 200600434A GT 200600434 A GT200600434 A GT 200600434A GT 200600434 A GT200600434 A GT 200600434A GT 200600434 A GT200600434 A GT 200600434A
Authority
GT
Guatemala
Prior art keywords
carbonitrils
tieno
piridin
inhibitors
protein kinase
Prior art date
Application number
GT200600434A
Other languages
English (en)
Inventor
Diane Harris Boschelli
Derek Cecil Cole
Magda Asselin
Ana Carolina Barrios Sosa
Biqi Wu
Lawrence Nathan Tumey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200600434A publication Critical patent/GT200600434A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE FORMULA GENERAL I EN LA QUE R1,R2,R3,R4,X, SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE. ESTOS COMPUESTOS SON CAPACES DE INHIBIR PROTEINAS QUINASAS POR LO QUE SON DE UTILIDAD EN ENFERMEDADES AUTOINMUNES E INFLAMATORIAS TALES COMO ASMA, ARTRITIS, ESCLEROSIS MULTIPLE DIABETES.
GT200600434A 2005-09-27 2006-09-27 Tieno[2,3-b]piridin-5-carbonitrilos como inhibidores de proteina quinasa GT200600434A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72082105P 2005-09-27 2005-09-27

Publications (1)

Publication Number Publication Date
GT200600434A true GT200600434A (es) 2007-05-28

Family

ID=37603099

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200600434A GT200600434A (es) 2005-09-27 2006-09-27 Tieno[2,3-b]piridin-5-carbonitrilos como inhibidores de proteina quinasa

Country Status (16)

Country Link
US (1) US20070082880A1 (es)
EP (1) EP1937690A1 (es)
JP (1) JP2009511439A (es)
KR (1) KR20080059184A (es)
CN (1) CN101273047A (es)
AR (1) AR056200A1 (es)
AU (1) AU2006294726A1 (es)
BR (1) BRPI0616758A2 (es)
CA (1) CA2623228A1 (es)
GT (1) GT200600434A (es)
NO (1) NO20081133L (es)
PE (1) PE20070619A1 (es)
RU (1) RU2008108619A (es)
TW (1) TW200745137A (es)
WO (1) WO2007038519A1 (es)
ZA (1) ZA200802690B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276519B2 (en) * 2002-11-25 2007-10-02 Wyeth Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
TW200821318A (en) * 2006-09-26 2008-05-16 Wyeth Corp Process for the preparation of 4-hydroxythieno[2,3-b]pyridine-5-carbonitriles
US20090118276A1 (en) * 2007-11-02 2009-05-07 Wyeth Thienopyrimidines, thienopyridines, and pyrrolopyrimidines as b-raf inhibitors
ES2555393T3 (es) * 2009-12-18 2015-12-30 Glaxosmithkline Intellectual Property Limited Nuevos compuestos
EP2611812A1 (en) * 2010-09-01 2013-07-10 Ambit Biosciences Corporation Thienopyridine and thienopyrimidine compounds and methods of use thereof
BR112013006272A2 (pt) 2010-09-17 2019-09-24 Purdue Pharma Lp compostos de piridina e seus usos
WO2012136120A1 (zh) * 2011-04-02 2012-10-11 中国人民解放军军事医学科学院毒物药物研究所 芳基丙烯酰胺化合物及其用于制备免疫抑制剂的用途
US9801863B2 (en) 2012-04-16 2017-10-31 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for modulating hematopoietic stem cells and hematopoiesis
US9790233B2 (en) * 2012-04-16 2017-10-17 Case Western Reserve University Compositions and methods of modulating 15-PGDH activity
CA2927730A1 (en) 2013-10-15 2015-05-07 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
JP2019512491A (ja) * 2016-03-11 2019-05-16 エーシー・イミューン・エス・アー 診断及び療法のための二環式化合物
JP7595413B2 (ja) 2016-11-30 2024-12-06 ケース ウエスタン リザーブ ユニバーシティ １５－ｐｇｄｈ阻害剤とコルチコステロイドおよび／またはｔｎｆ阻害剤との組み合わせならびにその使用
CA3052466A1 (en) 2017-02-06 2018-08-09 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
CA3120858A1 (en) 2018-11-21 2020-05-28 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
JP7458406B2 (ja) * 2018-12-21 2024-03-29 セルジーン コーポレーション Ｒｉｐｋ２のチエノピリジン阻害剤
JP2024530952A (ja) * 2021-08-10 2024-08-27 ジャコバイオ ファーマスーティカルズ カンパニー リミテッド ｐ５３変異体を標的とする化合物
CN114957280B (zh) * 2021-12-31 2024-09-17 成都赜灵生物医药科技有限公司 噻吩[2,3-d]嘧啶衍生物及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196207A (en) * 1977-05-23 1980-04-01 Ici Australia Limited Process for controlling eradicating or preventing infestations of animals by Ixodid ticks
CN1280580A (zh) * 1997-11-11 2001-01-17 辉瑞产品公司 用作抗癌药的噻吩并嘧啶和噻吩并吡啶衍生物
US5948911A (en) * 1998-11-20 1999-09-07 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to thienopyrimidine derivatives
GB9906566D0 (en) * 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
AU6578900A (en) * 1999-07-07 2001-01-30 Astrazeneca Uk Limited Quinazoline derivatives
WO2001066099A2 (en) * 2000-03-06 2001-09-13 Astrazeneca Ab Use of quinazoline derivatives as angiogenesis inhibitors
DE60106022T2 (de) * 2000-06-06 2006-03-09 Pfizer Products Inc., Groton Thiophenverbindungen zur verwendung als antikrebsmittel
US20020004511A1 (en) * 2000-06-28 2002-01-10 Luzzio Michael Joseph Thiophene derivatives useful as anticancer agents
WO2003000194A2 (en) * 2001-06-21 2003-01-03 Pfizer Inc. Thienopyridine and thienopyrimidine anticancer agents
AU2003237330A1 (en) * 2002-06-06 2003-12-22 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
CL2003002287A1 (es) * 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
US7276519B2 (en) * 2002-11-25 2007-10-02 Wyeth Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
US7674907B2 (en) * 2004-07-23 2010-03-09 Amgen Inc. Furanopyridine derivatives and methods of use
WO2006031929A2 (en) * 2004-09-15 2006-03-23 Janssen Pharmaceutica, N.V. Thiazolopyridine kinase inhibitors
CA2611370C (en) * 2005-05-20 2014-11-25 Oscar Mario Saavedra Inhibitors of vegf receptor and hgf receptor signaling

Also Published As

Publication number Publication date
PE20070619A1 (es) 2007-07-02
WO2007038519A1 (en) 2007-04-05
ZA200802690B (en) 2009-08-26
NO20081133L (no) 2008-04-25
JP2009511439A (ja) 2009-03-19
BRPI0616758A2 (pt) 2011-06-28
KR20080059184A (ko) 2008-06-26
AU2006294726A1 (en) 2007-04-05
EP1937690A1 (en) 2008-07-02
RU2008108619A (ru) 2009-11-10
US20070082880A1 (en) 2007-04-12
CA2623228A1 (en) 2007-04-05
TW200745137A (en) 2007-12-16
AR056200A1 (es) 2007-09-26
CN101273047A (zh) 2008-09-24

Similar Documents

Publication Publication Date Title
GT200600434A (es) Tieno[2,3-b]piridin-5-carbonitrilos como inhibidores de proteina quinasa
GT200500226A (es) Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteina quinasa
GT200500103A (es) 4-fenilamino-quinazolin-6-il-amidas
GT200800258A (es) Compuestos de pirrolo-pirimidina y sus usos
GT200600181A (es) Derivados de amida sustituida y metodos de uso
GT200500101A (es) Compuestos de metil-aril o heteroaril-amida sustituida
GT200300098A (es) Inhibidores de metaloproteinasa de aril-heteroariloxi-ariloxi-pirimidina-2,4,6-triona
GT200300093A (es) Inhibidores de metaloproteinasa de heteroariloxi-aril-espiro-pirimidina-2,4,6-triona n-sustituida
CR10343A (es) Aminotetrahidropiranos como inihibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes
GT200800103A (es) 5-aril isoxazolinas para controlar plagas de invertebrados
MX339476B (es) Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso.
GT200400173A (es) Compuestos de aril o heteroaril amida
GT200300072AA (es) Aminoacidos con afinidad por la proteina alfa2delta (solicitud fraccionaria
BRPI0520870B8 (pt) compostos intermediários para a preparação de alfa-mercaptoacetanilidas de s-triazolila
GT200300097A (es) Inhibidores de metaloproteinasa de triaril-oxi-aril-espiro-pirimidina-2,4,6-triona
BR112012022513A2 (pt) derivados de piperidin-4-il azetidina como inibidores de jak1
ATE548374T1 (de) 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren
ATE384061T1 (de) Imidazo- und thiazolopyridine als jak3-kinase- inhibitoren
GT200200224A (es) Benzamida, heteroarilamida y amidas inversas
GT200700035A (es) Piridin[3,4-b]pirazinonas
GT200400133A (es) Derivados de pirrolo[3,4-c] pirazol activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden
MX2013001977A (es) Proteinas osteogenicas de diseño.
GT200300033A (es) Derivados de nicotinamida utiles como inhibidores de pde4
EP2021792A4 (en) Dissolved protein arthritis markers
UY29149A1 (es) Tiazolil-dihidro-indazoles